

JAP3 Rec'd PCT/FTO 17 JAN 2006

\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	/	€ c	b
TA MABEMARM SE	U.S. DEPARTMENT O	F COMMERCE	
MABEMA	PATENT AND TRADE	MARK OFFICE	
SUPPLEMENTAL	INFORMATION	Docket Number:	
DISCLOSURE STATEMENT		11245/48503	
DISCLOSURE STA	ALEMENI		
Application Number	Filing date	Examiner	Art Unit
10/520,026	December 27, 2004	To Be Assigned	To Be Assigned
Invention Title		Inventor(s)	
BISPECIFIC ANTIBODIES THAT BIND TO VEGF RECEPTORS		ZHU, Zhenping	

Address to:

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: January p. 2006.

Layrence P. Casson (Reg. No. 46,606)

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
- 2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
- 3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
- 4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: January 9, 2006

By:

Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON LLP

One Broadway

New York, NY 10004

Tel: (212) 425-7200

Fax: (212) 425-5288

CUSTOMER NO. 26646

NY01 1077920 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO - 1449 FORM

ATTY. DOCKET NO. 11245/48503	SERIAL NO. 10/520,026
APPLICANT ZHU, Zhenping	
FILING DATE December 27, 2004	GROUP

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	6,383484	May 7, 2002	Achen et al.	·		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA YES	NO
-	WO 95/009917	April 13, 1995	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.		
·	Yang et al., CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anit-HIV-1 Antibody into the Picomolar Range. J. Mol. Biol. 1995, vol. 254, pages 392-403		
	Kortt et al., Single-chain Fv Fragments of Anit-neuraminidase Antibody NC10 containing Five-and tenresidue linkers Form Dimers and with Zero-residue Linker a Trimer. Protein Engineering 1997, Vol. 10, No. 4, pages 423-425		
	Lu, D. Complete Inhibition of Vascular Endothelial Growth Factor (VEGF) Activities with a Bifunctional Diabody Directed against Both VEGF Kinase Receptors, fms-like Tyrosine Kinase Receptor Cancer Research October 2001, Vol. 61. pages 7002-7008		
	Lu. D, Acquired Antagonistic Activity of a Bispecific Diabody Directed Against Tow Different Epitopes in Vascular Endothelial Growth Factor Receptor 2 J. Immunol. Methods November 1999, Vol. 230. No. 1-2, pages 159-171		

EXAMINER	DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and				
not considered. Include copy of this form with next communication to applicant.				